What Entex LA Treats: Main Uses and Benefits

Symptomatic Support for Respiratory Discomfort

This medication is commonly used to provide symptomatic support for symptoms related to the upper and lower respiratory tracts, primarily by managing congestion and thick mucus. It is applied in various instances where additional symptomatic support is required for respiratory relief.

It is relevant for addressing symptom clusters that may appear suddenly or intensify temporarily in conditions such as the common cold, flu, allergic rhinitis (hay fever), and congestion associated with sinusitis or bronchitis.

This sustained symptomatic support is relevant for easing two primary types of physical discomfort: the sensation of stuffy nose and sinus pressure, and the difficulty associated with clearing thick, bothersome phlegm from the chest. The combination of actions may assist in managing the difficult clearance of secretions and contributes to easing the overall symptom load.

It is commonly used across conditions presenting with acute episodes where patients experience the dual burden of nasal blockage and chest secretions.

---

Quick Fact: Relief for Stuffy Nose and Chest Congestion

The prolonged action is relevant when supportive symptom management is appropriate, helping to maintain a sense of stability when symptoms are more noticeable, and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH DailyMed website

This section outlines the official eligibility and non-eligibility information for Entex LA (Pseudoephedrine HCl / Guaifenesin), as documented in regulatory prescribing information.

Contraindicated Populations

Do not use this medicine if you have any of the following conditions or circumstances:

• Hypersensitivity or allergy to sympathomimetics (such as pseudoephedrine) or any component of the product.
• Severe hypertension (high blood pressure).
• Severe coronary artery disease.
• If you are currently receiving Monoamine Oxidase (MAO) inhibitors, or within 14 days of stopping such treatment.

Populations Requiring Caution or Restriction

Use of Entex LA is generally not recommended for the following groups:

• Children under 12 years of age.
• Pregnant women.
• Nursing (breastfeeding) women, as pseudoephedrine may reduce milk supply.

Caution is required and consultation with a healthcare professional is necessary if you have non-severe high blood pressure, heart disease, diabetes, thyroid disease (hyperthyroidism), glaucoma, or conditions leading to urinary obstruction (e.g., prostatic hypertrophy).

Interactions with Other Medicines and Products

Official regulatory documentation structures the interaction profile of Entex LA around specific medicinal product categories and timing constraints, primarily due to the sympathomimetic component, phenylephrine.

Medicines to Avoid

Strict warnings require the avoidance of this product if the patient is currently taking a Monoamine Oxidase Inhibitor (MAOI) or has used one within the past 14 days. This includes MAOIs such as phenelzine, tranylcypromine, isocarboxazid, and other agents with MAOI activity, such as linezolid or methylene blue injection, due to the high risk of hypertensive crisis.

Significant Interaction Categories

Co-administration with other sympathomimetics (including other decongestants or stimulants) is restricted, as this combination can increase the risk of cardiovascular and central nervous system effects. Additionally, the product may interfere with the effects of medicines used to treat high blood pressure, such as certain antihypertensives and beta-blockers, potentially reducing their therapeutic efficacy. Concurrent use with alcohol or other Central Nervous System (CNS) depressants should be avoided due to the potential for additive sedation.

Laboratory Interference

An interaction note exists concerning laboratory testing: the guaifenesin component has been reported to interfere with the clinical laboratory determination of urinary 5-hydroxyindole-acetic acid (5-HIAA) and vanillylmandelic acid (VMA), requiring consideration when these tests are performed.

The mechanism of action for this combination product involves two distinct and complementary pharmacodynamic pathways executed by its components, Pseudoephedrine and Guaifenesin.

1. alpha-Adrenergic Vasoconstriction in Mucosa

This domain covers the action of Pseudoephedrine, which targets alpha-adrenergic receptors on vascular smooth muscle. By acting as an agonist on these receptors, the drug initiates a cascade that causes vascular smooth muscle contraction (vasoconstriction) in the nasal and sinus linings, resulting in a decrease in local fluid extravasation and tissue engorgement.

2. Modulation of Tracheobronchial Secretion Rheology

This domain explains the mechanism of Guaifenesin, which acts indirectly via stimulation of vagal afferent nerve endings in the stomach, activating a reflex that signals respiratory glands. This process leads to an increase in the volume and water content of tracheobronchial secretions, thereby altering the viscoelasticity of mucus.

3. Mechanistic Synergy and Dual-Effect Profile

The two components operate simultaneously, affecting two distinct physiological aspects: the alpha-adrenergic mechanism modulates mucosal tissue volume, while the rheological modulation alters secretion viscoelasticity. This dual approach results in both the reduction of tissue engorgement and the enhancement of secretion flow dynamics in the upper respiratory system.

How to Use Entex LA: Administration Guidelines

This section describes the administration and dosage protocols for Entex LA, a combination product containing Guaifenesin and Pseudoephedrine. The medicine is formulated as an oral extended-release tablet and is intended for short-term, symptomatic use.

---

Administration Scope

Parameter	Instruction
Route of administration	Oral
Dosing schedule (Adults and children 12 years and older)	One (1) tablet of the 1200 mg/120 mg strength, or two (2) tablets of the 600 mg/60 mg strength. Maximum daily intake of Guaifenesin is 2400 mg and Pseudoephedrine is 240 mg.
Frequency and timing	Every 12 hours (twice daily).
Timing in relation to meals	Can be taken without regard to the timing of meals (with or without food).
Preparation requirements	Take the tablet with a full glass of water.
Age-group administration rules	The extended-release formulation is not for use in children under 12 years of age.
Course duration / cycle information	Intended for short-term use, generally for periods less than 7 days.

---

Special Procedural Conditions

• The extended-release tablet must be swallowed whole; the tablet should not be crushed, chewed, or broken. This ensures the intended prolonged release of the medication.
• If a regular dose is missed, it should be taken as soon as it is remembered. However, if it is near the time for the next scheduled dose, the missed dose should be skipped to avoid exceeding the maximum daily limits.

---

Connection to the Overall Use Protocol

The instructions establish an oral, twice-daily dosing protocol intended for short-term use. This protocol is defined by the requirement that the tablet be swallowed whole to preserve the extended-release function, and it includes explicit age restrictions on who can use this specific formulation. These components structure the administration of the medication.

Research Evidence / Overview of Studies for Entex LA

This overview describes the research that has been conducted on the combination of guaifenesin and pseudoephedrine (the active ingredients in Entex LA), focusing on the types of trials performed and what the overall findings suggest about the study patterns, without offering any medical advice or recommendations.

---

Evidence for Symptom Relief in the Common Cold and Acute URTIs

The primary evidence base for this combination therapy comes from Randomized Controlled Trials (RCTs). These short-term studies are conducted during periods of increased symptom activity, and they commonly involve comparing the medication to a non-active placebo pill. Researchers examined how symptoms change over time in adults presenting with acute symptoms from the common cold and other acute upper respiratory tract infections (URTIs), exploring outcomes related to nasal congestion and bothersome chest mucus.

Studies primarily monitored outcomes related to physical discomfort, specifically measuring changes in patient-reported scores for symptoms like nasal blockage, sinus pressure, and cough frequency. Findings report the patterns of change measured for these tracked symptoms over the course of the acute illness, which typically lasted for about seven days.

---

Research on the Long-Acting (LA) Formulation and Duration of Effect

A key focus of the evidence base is confirming the design of the extended-release (LA) tablet. These specific studies, known as Clinical Pharmacology or Bioequivalence Studies, were evaluated in healthy adult volunteers to track how the active ingredients are absorbed and maintained in the bloodstream. This research provides data on how the two components are released slowly over time.

These studies provide insight into short-term changes by monitoring drug levels in the blood over defined time intervals, typically up to 12 hours. This data was submitted to the regulatory review to demonstrate the necessary pharmacological profile for the extended-release format to sustain drug presence over the intended 12-hour period. Research describes these patterns, but these findings do not describe personal outcomes or determine whether an individual will respond similarly.

---

Research Gaps and What Remains Uncertain

The overall evidence landscape contributes to the broader understanding of symptom patterns but also highlights where knowledge is still developing. Research provides context but not individual predictions.

The primary limitation noted in scientific reviews is the difficulty in characterizing the clinical contribution of the expectorant component (guaifenesin). The research base for the decongestant component displays a pattern of more uniform findings in the published literature; however, the data describing how symptoms are measured for mucus thinning is often subjective or inconsistent. Furthermore, as the research explores short-term symptom changes, long-term effects are not fully established, and there is limited information regarding the duration of observed symptom patterns beyond the acute treatment phase.

Key Studies & References

1. DailyMed Labeling Information for Guaifenesin and Pseudoephedrine Extended-Release Tablets

Common questions about Entex LA (FAQ)

---

Q: Is it mandatory to take Entex LA with food, or can it be taken on an empty stomach?

Official administration guidelines state that this medication can be taken without regard to the timing of meals. This means it is acceptable, according to the regulatory documentation, to take the extended-release tablet either with food or on an empty stomach.

---

Q: What should I do if I miss a dose of the medication?

If a regular dose is missed, regulatory guidance indicates it should be taken as soon as it is remembered. However, to prevent exceeding maximum daily limits, the missed dose is typically skipped entirely if it is almost time for the next scheduled dose. Taking a double dose to compensate for a missed dose is generally avoided.

---

Q: How do I properly store my Entex LA tablets?

According to the product information, Entex LA should be stored at controlled room temperature, which is typically between 15^circC and 30^circC (59^circF and 86^circF). Regulatory storage instructions specify that the container should be kept tightly closed and protected from excessive moisture, heat, and direct sunlight.

---

Q: What should I do with my unused or expired Entex LA?

Government guidelines for medicine disposal advise that unused or expired tablets should generally not be flushed down a toilet or sink. Disposal methods outlined in general guidance include mixing the medication with an unappealing substance, such as coffee grounds or cat litter, placing the mixture in a sealed bag, and discarding it in the household trash. It is also advised to check with local pharmacies or law enforcement for authorized drug take-back programs.

---

Q: What part of the body does Pseudoephedrine affect to relieve congestion?

Pseudoephedrine, the decongestant component, acts on blood vessels in the lining of the nose and sinuses. It functions by causing the blood vessels in these areas to narrow, a process called vasoconstriction. This action reduces swelling and tissue engorgement, which helps alleviate the sensation of congestion.

---

Q: What is the recommended maximum number of days I should take Entex LA?

Official regulatory guidance advises that treatment with this medication should be discontinued if symptoms do not improve within seven days of use. Discontinuation is also advised if symptoms are accompanied by a fever, rash, or persistent headache.

---

Q: What are the warning signs of an allergic reaction to Entex LA?

The official safety profile advises vigilance for signs of a serious allergic reaction, as can occur with any medication. These warning signs may include swelling of the face, lips, tongue, or throat, hives, or developing difficulty breathing.

How to Store and Dispose of Entex LA?

This section provides official storage and disposal requirements for Entex LA.

---

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, typically between 59°F and 86°F (15°C and 30°C).
Protection	Keep the container tightly closed. Protect from excessive heat, moisture, and direct sunlight.
Access	Store in a secure location, out of the sight and reach of children.

Disposal Instructions

Leftover Entex LA must be disposed of safely. Do not share this medication. Follow local guidelines for proper disposal of unused or expired medications. Consult a healthcare professional or pharmacist if you have questions about storage or disposal.